Key Highlights
- Market futures declined Tuesday morning as crude oil neared the $100 threshold, intensifying speculation about further Fed rate increases
- Intel topped S&P 500 premarket advancers, joined by AMD and Marvell on strengthening AI semiconductor momentum
- Novartis plunged 13% following failure of its muscle-wasting treatment trial, pulling Sarepta and Dyne Therapeutics down
- Roivant Sciences surged 20% on encouraging Phase 2 data from its subsidiary’s lung disease therapy
- ASML gained 2% after major chipmakers Samsung, TSMC, and Intel validated adoption plans for advanced lithography equipment
U.S. equity futures trended downward Tuesday as Brent crude prices maintained levels above $98 per barrel. The sustained oil price elevation is amplifying market predictions that the Federal Reserve may implement another interest rate increase during its upcoming policy meeting.
Bucking the negative market sentiment, semiconductor stocks focused on artificial intelligence applications posted gains during early trading. Intel emerged as the leading S&P 500 performer in premarket activity, climbing 3.6%. Peers including Advanced Micro Devices and Marvell posted similar advances, with Micron and Sandisk also participating in the rally.
Semiconductor Sector Shows Strength
ASML contributed to the upbeat chip sector momentum, advancing 2% following confirmation that Samsung, Taiwan Semiconductor Manufacturing, and Intel remain committed to implementing its High-NA extreme ultraviolet lithography systems.
According to ASML’s Chief Technology Officer, an anticipated transition from 6-inch to 12-inch photomask technology could enhance equipment throughput by as much as 40%. TSMC and ASML have established objectives for a 12-inch mask testing facility by 2031, with full-scale commercial manufacturing anticipated by 2033.
Roivant Sciences captured the spotlight as Tuesday’s strongest performer, soaring 20%. The company’s Pulmovant division announced favorable Phase 2 clinical data for mosliciguat, an experimental therapy targeting pulmonary hypertension associated with interstitial lung disease.
The experimental treatment achieved its primary efficacy measure, demonstrating an approximate 56% reduction in pulmonary vascular resistance versus placebo. Additional benefits included enhancement of six-minute walking capacity by roughly 35 meters and a 53% decrease in a critical cardiac stress biomarker.
Biotech Sector Weakens Following Novartis News
Novartis tumbled 13% after reporting that its advanced-stage clinical study for muscle-wasting therapy del-desiran did not achieve its primary efficacy goal. This marked the pharmaceutical giant’s third consecutive clinical disappointment within a seven-day period.
The trial failure created a negative cascade throughout biotechnology equities. Dyne Therapeutics plummeted 30%, Sarepta Therapeutics declined 11%, and NewAmsterdam Pharma retreated 9%.
The Novartis news also pressured Amgen, which slid nearly 5%. Amgen is advancing its proprietary cardiovascular therapy olpasiran, prompting investors to reassess similar development programs following the wider clinical disappointment.
Novartis’s Chief Medical Officer characterized the setbacks as inherent elements of scientific advancement. The pharmaceutical company maintained its 5% to 6% annual sales expansion forecast extending through 2030.
Zim Integrated Shipping Services advanced 6% after Hapag-Lloyd and private equity partner FIMI announced plans to modify their proposed $4.2 billion acquisition following discussions with Israeli authorities.
The transaction has encountered resistance within Israel from labor organizations, defense authorities, and government representatives citing national security concerns. Hapag-Lloyd verified it is collaborating with Israeli officials on structural modifications to address these issues.
Fuel-cell developer Bloom Energy rose 5.9%, data storage company Everpure increased 3%, and biotechnology firm Illumina ticked up 0.9%. These three companies are scheduled for S&P 500 inclusion on September 21.
Builders FirstSource, Molson Coors Beverage, and Trade Desk face removal from the S&P 500, with all three declining Tuesday.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
